2023 - Research.com Medicine in Belgium Leader Award
His primary areas of study are Lung cancer, Internal medicine, Oncology, Surgery and Carcinoma. His Lung cancer study combines topics from a wide range of disciplines, such as Positron emission tomography, Radiology, Nuclear medicine, Stage and Survival analysis. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Placebo.
His study in Oncology is interdisciplinary in nature, drawing from both KRAS, Disease, Evidence-based medicine, Docetaxel and Gemcitabine. The study incorporates disciplines such as Clinical trial and Anemia in addition to Surgery. The various areas that Johan Vansteenkiste examines in his Clinical trial study include Atypical adenomatous hyperplasia, Tolerability and Predictive marker.
Johan Vansteenkiste mainly focuses on Internal medicine, Oncology, Lung cancer, Surgery and Chemotherapy. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. In his research, Atezolizumab is intimately related to Docetaxel, which falls under the overarching field of Oncology.
His Lung cancer study integrates concerns from other disciplines, such as Stage, Clinical trial, Radiology and Carcinoma. Johan Vansteenkiste has included themes like Metastasis and Lymph node in his Radiology study. His Surgery study deals with Placebo intersecting with Hazard ratio.
Internal medicine, Oncology, Lung cancer, In patient and Cancer research are his primary areas of study. His study in Osimertinib, Chemotherapy, Durvalumab, Docetaxel and Chemoradiotherapy is carried out as part of his studies in Internal medicine. His Oncology research is multidisciplinary, relying on both Nivolumab, Atezolizumab and Clinical trial.
Johan Vansteenkiste has researched Lung cancer in several fields, including Carcinoma, Radiology and Immunotherapy. His work investigates the relationship between Radiology and topics such as Randomized controlled trial that intersect with problems in Stage. His Cancer research research includes elements of KRAS, Capmatinib and Kinase.
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Osimertinib and Cancer research. Johan Vansteenkiste works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Confidence interval, as a part of the same area of interest. His Oncology research is multidisciplinary, incorporating perspectives in Stage and Immunohistochemistry, Clinical trial, Pathology.
His Lung cancer study incorporates themes from Carcinoma and Docetaxel. Johan Vansteenkiste focuses mostly in the field of Osimertinib, narrowing it down to matters related to T790M and, in some cases, EGFR T790M, Discontinuation, Erlotinib Hydrochloride, Dacomitinib and Survival rate. His work on Stromal cell as part of general Cancer research research is frequently linked to Profiling, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma.
Journal of Clinical Oncology (2008)
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura.
Journal of Clinical Oncology (2003)
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana.
The New England Journal of Medicine (2018)
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Arriagada R;Bergman B;Dunant A;Le Chevalier T.
The New England Journal of Medicine (2004)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta.
Journal of Thoracic Oncology (2016)
Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial
Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz.
The Lancet (2016)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
S Novello;F Barlesi;R Califano;R Califano;T Cufer.
Annals of Oncology (2010)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia;Augusto Villegas;Davey Daniel;David Vicente.
The New England Journal of Medicine (2018)
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan.
The New England Journal of Medicine (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: